Notman Donald 4
4 · OCULAR THERAPEUTIX, INC · Filed Feb 4, 2026
Research Summary
AI-generated summary of this filing
Ocular Therapeutix (OCUL) COO Donald Notman Sells Shares
What Happened Donald Notman, Chief Operating Officer of Ocular Therapeutix, sold a total of 11,490 shares of OCUL stock in two open-market transactions to cover tax withholding tied to restricted stock unit (RSU) vestings. On 2026-02-02 he disposed of 5,455 shares at a weighted average price of $9.14 for proceeds of $49,859; on 2026-02-04 he disposed of 6,035 shares at a weighted average price of $8.54 for proceeds of $51,539. Total proceeds were about $101,398. The sales were non-discretionary sell-to-cover transactions (not open-market directional trades by the insider).
Key Details
- Transaction dates and prices:
- 2026-02-02: 5,455 shares sold, weighted avg $9.14 (price range $9.0565–$9.3217) — $49,859 (F1, F2)
- 2026-02-04: 6,035 shares sold, weighted avg $8.54 (price range $8.4377–$8.6769) — $51,539 (F3, F4)
- Reason: Sales executed under a durable automatic sales instruction (sell-to-cover) to satisfy tax withholding related to RSU vesting (vest dates Jan 30, 2026 and Feb 3, 2026). The filing states these were not discretionary trades.
- Additional note: The filer offers to provide detailed per-price breakdowns on request (per footnotes).
- Shares owned after the transactions: not specified in the provided filing.
- Filing date: Form 4 filed 2026-02-04 covering the above transactions; no late-filing indication provided in the materials supplied.
Context
- These transactions are routine tax-withholding "sell-to-cover" dispositions of vested RSUs (transaction code F), not purchases or voluntary sales intended as a market signal. For retail investors, such sales generally do not by themselves indicate insider sentiment about company prospects.
Insider Transaction Report
Form 4
Notman Donald
Chief Operating Officer
Transactions
- Sale
Common Stock
[F1][F2]2026-02-02$9.14/sh−5,455$49,859→ 383,837 total - Sale
Common Stock
[F3][F4]2026-02-04$8.54/sh−6,035$51,539→ 377,802 total
Footnotes (4)
- [F1]Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sales instruction letter dated May 13, 2022, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 30, 2026. The sales do not represent a discretionary trade by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.0565 to $9.3217, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- [F3]Represents shares of common stock of the Corporation sold, pursuant to a durable automatic sales instruction letter dated May 13, 2022, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 3, 2026. The sales do not represent a discretionary trade by the reporting person.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.4377 to $8.6769, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
Signature
/s/ Todd Anderman, Attorney-in-Fact for Donald Notman|2026-02-04